A Review of Barrett\u27s Esophagus by Zayan, Suzanne M.
University of North Dakota
UND Scholarly Commons
Physician Assistant Scholarly Project Posters Department of Physician Studies
2016
A Review of Barrett's Esophagus
Suzanne M. Zayan
University of North Dakota
Follow this and additional works at: https://commons.und.edu/pas-grad-posters
Part of the Gastroenterology Commons
This Poster is brought to you for free and open access by the Department of Physician Studies at UND Scholarly Commons. It has been accepted for
inclusion in Physician Assistant Scholarly Project Posters by an authorized administrator of UND Scholarly Commons. For more information, please
contact zeineb.yousif@library.und.edu.
Recommended Citation
Zayan, Suzanne M., "A Review of Barrett's Esophagus" (2016). Physician Assistant Scholarly Project Posters. 91.
https://commons.und.edu/pas-grad-posters/91
A REVIEW OF BARRETT’S ESOPHAGUS
Suzanne M. Zayan PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
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Abstract
Introduction
• Barrett's Esophagus (BE) is a pre-malignant, dysplastic 
condition of the distal esophagus that predisposes patients to 
the development of esophageal adenocarcinoma 
• Gastroesophageal reflux disease is the precursor to the 
development of BE, up to 15% of adults in the United States 
have Barrett’s Esophagus. 
Research Question




• Several risk factors identified in the literature review influence 
progression of neoplastic transition in BE. These include male 
gender, advanced age, hiatal hernia, GERD, ethnicity, smoking, 
poor dietary intake of fruits and vegetables, the type of 
dysplasia and length of the BE segment. Accurate description 
and confirmation of biopsies by a second expert pathologist, is 
highly recommended.
• RFA is proven to be a successful intervention to eradicate IM. 
Implementation of early treatment of BE demonstrates lower 
progression rates of LGD-BE to EAC. 
• There is not a confirmed number of RFA treatments that can 
determine long term remission rates of BE or definitive stop 
time for endoscopic surveillance.
• More studies are needed to determine long term (>5yrs) 
success of early eradication of LGD. 
• There is controversy between studies regarding whether the 
extent and length of LGD is a predictor of progression to EAC. 
Being male doubled the risk for GERD patients to develop BE 
which further doubled the risk of BE patients to develop EAC.
• Evidence supports the efficacy and durability of RFA.  
Predictors for success for achieving CRIM are related to 
younger age and shorter initial BE segment length. Advanced 
age was associated with a higher grade of BE and 
advancement to EAC. 
• The progression of cellular changes in BE is inconsistent, but 
the risk factors associated with disease progression are clear. 
Guidelines provided by various gastroenterology societies can 
assist practitioners to determine patient care management for 
endoscopic screening, therapy and disease surveillance. 
Barrett’s Esophagus is a premalignant condition that 
predisposes patients to the development of esophageal 
adenocarcinoma.
• Esophageal adenocarcinoma dramatically rising over  several 
decades; survival rates of less than 17% in a five year period.
• Management and treatment continues to evolve: use of radio-
frequency ablation effective to treat low grade dysplasia
• Studies of risk factors and treatment options explored:
Efficacy and durability of endoscopic radiofrequency ablation 
for treatment of low grade dysplasia as option for metaplasia 
eradication
– Gastrointestinal pathologist expert reviews ensure 
identification of dysplasia prior to treatment
– Appropriate endoscopic surveillance intervals
– Gastroenterology guidelines for screening and  surveillance 
for long term management
– Lifelong endoscopic surveillance individualized to monitor 
for recurrence of metaplasia
• In adult patients with non-dysplastic or low grade dysplasia BE, 
as compared to high grade dysplasia BE, what risk factors 
predict the progression to EAC?
• In adult patients diagnosed with low grade dysplasia BE, does 
earlier treatment with RFA, compared to standard intermittent 
endoscopic surveillance, reduce the progression to EAC?
• In adult patients with complete eradication of Barrett’s 
esophagus, what influences the recurrence of dysplastic 
progression after successful RFA?
• Primary care providers need to consistently identify risk factors 
such as age, race, diet, tobacco, obesity and duration of GERD 
symptoms when determining candidates for early endoscopic 
screening for BE. 
• Factors that predict the progression of non-dysplastic BE to EAC 
include the initial dysplasia histology and the length of the BE 
segment.
• Counsel and teach patients regarding control of modifiable risk 
factors with emphasis of tobacco cessation and management of 
co-morbidities. 
• A diagnosis of EAC has poor survival rates. Risk stratification 
can help patients make and maintain good decisions for a better 
overall health outcome. 
• Establish a trusting provider to patient relationship so facts 
regarding BE and the risks of progression to EAC can be clearly 
shared and communicated. 
• Endoscopic therapy with radiofrequency ablation is now the 
standard of care for treatment of dysplastic BE. It has high rates 
of success and durability when used alone or in combination 
with other gastric therapy. 
• Follow-up should be individualized, and treatment decisions 
should reflect consideration of current guidelines. Lifestyle 
modification should be exhausted before ablative therapy is 
decided. 
I wish to thank the Physician Assistant Studies Department 
advisors, instructors, and administrators for their support and 
guidance throughout my education at the University of North 
Dakota School of Medicine and Health Sciences, whose 
commitment to my success made this project possible.
Statement of the Problem
• Recommendations for the management and treatment of 
Barrett’s esophagus continue to evolve, now expanding the use 
of radio-frequency ablation (RFA) for the treatment of low grade 
dysplasia BE, previously observed with endoscopic surveillance 
until advancement to high grade dysplasia.
• Risk factors associated with the development of Barrett’s 
esophagus need to be studied due to the increasing burden of 
conditions associated with the progression to esophageal 
adenocarcinoma.
• More studies are needed to evaluate the long term efficacy and 
durability of early endoscopic RFA and the appropriate 
surveillance intervals to further determine  successful treatment 
of dysplastic BE and reduction of EAC.
References
Bulsiewicz, W., Kim, H., Dellon, E., Cotton, C., Pasricha, S., Madanick, R., . . 
. Shaheen, N. (2013). Safety and efficacy of endoscopic mucosal therapy 
with radiofrequency ablation for patients with neoplastic barrett’s esophagus. 
Clinical Gastroenterology and Hepatology, 11, 636-642. 
doi:10.1016/j.cgh.2012.10.028
Gupta, M., Iyer, P. G., Lutzke, L., Gorospe, E. C., Abrams, J. A., Falk, G. W., 
. . . Wang, K. K. (2013). Recurrence of esophageal intestinal metaplasia 
after endoscopic mucosal resection and radiofrequency ablation for barrett’s
esophagus: results form a US multicenter consortium. Gastroenterology, 
145, 79-86. doi:10.1053/j.gastro.2013.03.008
Pasricha, S., Bulsiewicz, W., Hathorn, K., Komanduri, S., Muthusamy, V.R., 
Rothstein, R.,…Shaheen, N. (2014). Durability and predictors of successful 
radiofrequency ablation fro Barett’s esophagus. Clin Gastroenterol Hepatol, 
12 (11), 1840-1847. doi:10.1016/j.cgh.2014.04.034.
Phoa, N., Frederike, G. I., van Vilsteren, F., Bas, L., Weustyen, A.M., 
Bisschops, B.,...Bergman, J. (2014). Radiofrequency ablation vs endoscopic 
surveillance for patients with barrett esophagus and low grade dysplasia. 
JAMA, 311 (12), 1209-1217. doi:10.1001/jama.2014.2511
Shaheen, N. J., Falk, G. W., Iyer, P. G., Gerson, L. B. (2015). ACG clinical 
guideline: diagnosis and management of barrett’s esophagus. American 
Journal of Gastroenterology. Advance online publication. 
doi:10.1038/ajg/.2015.322
Shaheen, N. J., Overholt, B. F., Sampliner, R. E., Wolfsen, H. C., Wang, K. 
K., Fleischer, D. E., Lightdale, C. J. (2011). Durability of radiofrequency 
ablation in barrett's esophagus with dysplasia. Gastroenterology, 141, 460-
468. doi:10.1053/j.gastro.2011.04.061
Wani, S., Falk, G. W., Post, J., Yerian, L., Hall, M., Wang, A., . . . Sharma, P. 
(2011). Risk factors for progression of low-grade dysplasia in patients with 
barrett’s esophagus, Gastroenterology, 141, 1179-1186. 
doi:10.1053/j.gastro.2011.06
Review of the updated recommendations with consideration of 
identified risk factors is essential to ensure adequate diagnosis 
and treatment of BE considering the devastation of progression to 
EAC.
• Pathophysiology of Barrett’s Esophagus
Main precursor for development of BE is a chronic reflux of 
stomach acids into the lower esophagus, inducing a 
premalignant condition in which normal squamous epithelial 
lining of the esophagus is replaced with columnar epithelium 
and goblet cells, known as intestinal metaplasia. Degrees of 
neoplastic change occur during the sequence of epithelial 
transition predisposing to the development of EAC. 
• Risk factors for the dysplastic transitions in BE and EAC
• Wani, et al. (2011), the Barrett’s Esophagus Study (BEST), 
identified risk factors for progression of LGD to EAC to include 
BE length, age > 60, presence of hiatal hernia, and Caucasian 
male. Pohl, et al. (2013), reported combinations of certain risk 
factors influence disease progression at different times. Singh, 
et al. (2014), found the grade of dysplasia, the length of the BE 
segment, and the use of expert pathologists determined 
progression of BE to EAC. 
• Early RFA treatment in BE-LGD to reduce the progression 
to EAC
• Shaheen et al. (2011), in the AIM Dysplasia Trial, found early 
dysplastic BE can be successfully treated with RFA with a 
durability of up to three years. The SURF study (Surveillance vs 
Radiofrequency Ablation) by Phoa, et al. (2014) reported the 
ablation group risk for progression to HGD/EAC was reduced by 
25.0 % (95% CI, 14.1%-35.9 %; P, .001) and the risk of 
neoplastic progression to EAC by 7.4% (95%CI, 0%-14.7%; 
P=.03). Bulsiewicz et al. (2013) found 77% of the patients, 
achieved complete eradication of intestinal metaplasia after  
RFA despite the degree of dysplasia. Success of RFA depended 
on healing time between RFA treatments and the length of the 
BE segment.
• Determine effective follow-up endoscopic surveillance 
intervals after RFA.
• Gupta, et al. (2013) analyzed data regarding return of intestinal 
metaplasia after successful RFA. The median time to CRIM was 
22 months with 56% in complete remission by 24 months. The 
findings suggest the importance of longer term endoscopic 
surveillance follow up after successful RFA in subjects with 
varying degrees of BE dysplasia.
Gastroenterology Society Screening Surveillance NDBE Surveillance LGD Surveillance HGD
American Gastroenterology 
Association
Screen for patients with multiple risk 
factors: >50 yr. old, male, white race, 
chronic GERD, Hiatal hernia, elevated 
body mass index, intra-abdominal 
distribution of body fat. No screening 
for general population
No dysplasia, surveillance every 
3-5 years
Low grade dysplasia: every 
6-12 months
High grade dysplasia unable to 
eradicate: every 3 months
American Society for 
Gastrointestinal Endoscopy
Consider endoscopic screening in 
patients with multiple risk factors for 
BE and EAC, inform patients this is not 
a cancer prevention
Consider no surveillance, or 
every 3-5 yrs. with 4-quadrant 
biopsies, ablation in select 
cases
Confirm with GI expert; 
repeat EGD in 6 mo. to 
confirm LDG; Yearly 
surveillance; Endoscopic 
resection or ablation if 
warranted
Confirm with GI expert; 
Consider surveillance EGD 3 
mo. in select patients; 
Endoscopic resection, RFA, or 
surgical consultation
American College of 
Physicians
Upper endoscopy in men >50 yr. old 
with chronic GERD and additional risk 
factors
Surveillance evaluation for men and women with history of BE; BE without dysplasia, 
surveillance frequency 3-5 yr. more frequent in patients with BE and dysplasia
• Pasricha, et.al (2014) utilized the RFA registry to determine how 
treatments with RFA and pretreatment data affected outcomes 
for biopsies 12 months after the receiving RFA. CEIM was 
achieved in 85% of these patients and 15% had persistent 
dysplasia. During the average follow up of 2.4 years after CRIM, 
IM recurred in 334 (20%) patients. Compared to patients 
without recurrence, patients with recurrence after successful 
CRIM, were found to be non-Caucasian, older age, have longer 
BE segments, and require higher numbers of RFA treatment 
sessions. 
Gastroenterology societal guidelines for screening and surveillance in Barrett’s Esophagus
